-
-
-
-
-
Stem Cell Therapy: 5 Major Challenges
Biotech
Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
-
BioNTech Acquires CureVac in $1.25B mRNA Deal
BioNTech
BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
新巴尔虎左旗|
郴州市|
都江堰市|
博白县|
驻马店市|
七台河市|
古浪县|
金堂县|
兰西县|
个旧市|
濮阳县|
迁西县|
六枝特区|
淄博市|
鄯善县|
余干县|
轮台县|
含山县|
雅江县|
张家口市|
瑞金市|
马龙县|
乡宁县|
湖州市|
龙川县|
商都县|
莲花县|
南江县|
新源县|
平顺县|
阿城市|
福清市|
滕州市|
张家界市|
岳普湖县|
原平市|
仙居县|
洪湖市|
孟津县|
随州市|
长沙市|